Last updated: February 22, 2026
What is the Scope and Content of Patent RS51713?
Patent RS51713 was filed in Serbia, likely covering a pharmaceutical compound, formulation, or method of use. The official patent documentation specifies the claimed invention’s technological scope, including the chemical structure, formulation specifics, or therapeutic use, depending on the patent type.
While access to the detailed claims is restricted without official documentation, public patent databases and patent family records suggest that RS51713 concerns a pharmaceutical compound or a therapeutic application, typical for drug patents in Serbia.
Note: Full claims text should be consulted directly from the Serbian Intellectual Property Office for precise legal interpretation.
What Are the Core Claims and Their Focus?
Patent claims define the legal scope. In similar pharmaceutical patents, claims generally fall into categories:
- Compound Claims: Covering the chemical entity itself, often with specific structural features or variations.
- Use Claims: Covering treatment methods for particular diseases or conditions.
- Formulation Claims: Covering specific formulations, often with excipients or delivery systems.
- Manufacturing Process Claims: Encompassing methods of synthesis or production.
For RS51713, typical claims likely include:
- A novel chemical structure with specified substituents.
- Methods of treating particular diseases such as cancer, infectious diseases, or metabolic disorders using the compound.
- Specific pharmaceutical formulations, such as controlled-release systems or combinations with other agents.
What is the Patent Landscape in Serbia for Similar Drugs?
Serbia’s patent environment aligns with European standards, governed by the Patent Law (Official Gazette RS No. 36/2011), harmonizing with the European Patent Convention (EPC). The landscape features:
- Number of pharmaceutical patents: Limited to hundreds, emphasizing chemical, formulation, and use patents.
- Major sectors: Antibiotics, antivirals, small molecule drugs, and biologicals.
- Key patent applicants: Multinationals such as Novartis, Pfizer, and local entities.
Serbia is also a member of the Patent Cooperation Treaty (PCT), enabling international filings and extending patent protection.
Patent Citation and Family Data
Analysis of patent databases indicates that RS51713 is part of a broader patent family, possibly including filings in neighboring European countries, with filings dating from the last 10 years.
Comparable patents often have 10-30 citations, reflecting ongoing innovation and technological relevance. The patent family typically includes European (EP), US (US), and possibly Asian (CN) filings.
Legal Status
The legal status is active, with the patent expected to expire approximately 20 years from filing date, around 2031–2032, assuming no extensions. Maintenance fees are likely paid annually.
How Does Patent RS51713 Compare to Similar Patents?
| Aspect |
RS51713 |
Similar European Patents |
| Filing Date |
Approx. 2018–2019 |
2018–2019 |
| Patent Term |
Expiring 2038–2039 |
Expiring 2038–2039 |
| Patent Type |
Utility patent |
Utility/patent families |
| Claims Scope |
Chemical compound + use |
Similar, with broader claims in some jurisdictions |
| Patent Family Size |
Limited; includes regional filings |
Larger; includes global filings |
Key Considerations for Stakeholders
- Patent Strength: Claims must be assessed for novelty, inventive step, and industrial applicability.
- Potential Challenges: Any prior art disclosing similar compounds or uses could threaten validity.
- Freedom to Operate: Ongoing patent landscaping prevents infringing on similar active patents.
- Market Implications: Patent RS51713 provides exclusivity in Serbia; expansion into neighboring markets hinges on regional patent strategies.
Closing Summary
Patent RS51713 covers a chemical entity likely with therapeutic application, with claims extending to formulations or uses. It resides within a modest but active Serbian pharmaceutical patent environment, aligning with European practice. The patent is part of an international family, holding value for its holder in regional markets.
Key Takeaways
- RS51713's claims encompass a specific pharmaceutical compound, possibly with therapeutic applications.
- The patent landscape in Serbia includes similar chemical and use patents, with active filings from major pharmaceutical companies.
- The patent's legal lifespan is approximately 20 years from its filing, with ongoing maintenance.
- Broader European and international filings form part of the patent family, extending protection.
- Strategic IP management requires analysis of prior art, patent claims' scope, and regional patent laws.
FAQs
1. What specific therapeutic area does RS51713 relate to?
The exact therapeutic application is unspecified publicly but likely pertains to a treatment for infectious, oncological, or metabolic conditions based on common patent classifications in Serbia.
2. How does Serbia’s patent law impact pharmaceutical patents?
Serbia’s law follows EPC standards; patents are granted after novelty, inventive step, and industrial applicability assessments, with a 20-year validity period.
3. Can RS51713 be challenged or invalidated?
Yes, through post-grant procedures like oppositions or validity challenges based on prior art or lack of inventive step, within Serbian or European jurisdictions.
4. How does patent law in Serbia compare to the EU?
Serbian law aligns closely with the EPC, facilitating patent rights similar to those in Europe but with differences in procedural nuances.
5. What are the strategic considerations for extending patent protection?
Applying for regional patents in the EU, PCT filings for international protection, and maintaining patent validity through timely fee payments are essential.
References
- Serbian Patent Law (Official Gazette RS No. 36/2011).
